Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/1b Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer

NCT02943317 is registered in ClinicalTrials.gov with Verastem, Inc. as lead sponsor.

NCT NCT02943317
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02943317 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/1b Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer
Lead sponsor
Verastem, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
October 31, 2016
Completion date
December 28, 2018
Enrollment
98 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

epithelial ovarian cancer